

14<sup>th</sup> November, 2019

(1) BSE Ltd.  
Listing Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

(2) National Stock Exchange of India Ltd.  
Listing Department  
Exchange Plaza, 5<sup>th</sup> floor,  
Plot no. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai - 400 051

**Scrip Code: 500087**

**Scrip Code: CIPLA**

(3) SOCIETE DE LA BOURSE DE  
LUXEMBERG  
Societe Anonyme  
35A Boulevard Joseph II,  
L-1840 Luxembourg

**Sub: USFDA routine cGMP inspection completed at Cipla's manufacturing facility in Patalganga**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the United States Food and Drug Administration (USFDA) conducted a routine cGMP inspection for both Formulations and APIs at our manufacturing facility in Patalganga from 4<sup>th</sup> November, 2019 to 13<sup>th</sup> November, 2019.

The inspection ended with 4 observations, none of which were repeat or related to data integrity. The Company is committed to addressing these observations and will submit its response to the agency within the stipulated time.

Kindly take the above information on record.

Thanking you,

Yours faithfully,  
For **Cipla Limited**

*K. Tanna*



**Karan Tanna**  
**Associate Director**  
**Corporate Secretarial**

Prepared by: Soham Alwani